2025 United States Antibodies Market Revenue Opportunities Report
Description
The 2025 United States Antibodies Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antibodies market are Roche, Amgen, Novartis, and Merck & Co. Roche, a Swiss multinational, leads with strong oncology and immunology biologics portfolios, including bispecific antibodies targeted at cancer and autoimmune diseases. Amgen is a major U.S.-based biopharmaceutical firm heavily invested in antibody therapeutics for cancer and inflammation. Novartis focuses on hematology, immuno-oncology, and rare diseases, leveraging strategic acquisitions and global expansion to strengthen its position. Merck & Co. concentrates on oncology and autoimmune indications with a robust bispecific antibody pipeline and strategic collaborations for next-generation therapies.
In addition to these, Pfizer and Thermo Fisher Scientific also have substantial antibody research and production operations in the U.S., primarily targeting monoclonal antibodies and research antibodies. Companies such as Abcam and Cell Signaling Technology are prominent in the U.S. research antibody market, which is estimated at over USD 559 million (2023) with a growth trajectory fueled by cancer, autoimmune, and stem cell research demands. The U.S. antibody market is projected to grow significantly, driven by innovation in immuno-oncology and a high number of clinical trials and FDA approvals.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the U.S. antibodies market are Roche, Amgen, Novartis, and Merck & Co. Roche, a Swiss multinational, leads with strong oncology and immunology biologics portfolios, including bispecific antibodies targeted at cancer and autoimmune diseases. Amgen is a major U.S.-based biopharmaceutical firm heavily invested in antibody therapeutics for cancer and inflammation. Novartis focuses on hematology, immuno-oncology, and rare diseases, leveraging strategic acquisitions and global expansion to strengthen its position. Merck & Co. concentrates on oncology and autoimmune indications with a robust bispecific antibody pipeline and strategic collaborations for next-generation therapies.
In addition to these, Pfizer and Thermo Fisher Scientific also have substantial antibody research and production operations in the U.S., primarily targeting monoclonal antibodies and research antibodies. Companies such as Abcam and Cell Signaling Technology are prominent in the U.S. research antibody market, which is estimated at over USD 559 million (2023) with a growth trajectory fueled by cancer, autoimmune, and stem cell research demands. The U.S. antibody market is projected to grow significantly, driven by innovation in immuno-oncology and a high number of clinical trials and FDA approvals.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
